AVONEX

LOE Approaching

interferon beta-1a

BLAINTRAMUSCULARVIALPriority Review
Approved
May 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
27

Mechanism of Action

12.1 Mechanism of Action The mechanism of action by which AVONEX exerts its effects in patients with multiple sclerosis is unknown. 12.2 Pharmacodynamics Interferons (IFNs) are a family of naturally occurring proteins, produced by eukaryotic cells in response to viral infection and other biologic…

Pharmacologic Class:

Interferon beta

Indications (1)

Clinical Trials (5)

NCT04655222N/ACompleted

Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program

Started Apr 2021
470 enrolled
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
NCT03958877Phase 3Active Not Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Started Oct 2019
152 enrolled
Multiple Sclerosis, Relapsing-Remitting
NCT03870763Phase 3Terminated

Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

Started Mar 2019
11 enrolled
Multiple Sclerosis, Relapsing-Remitting
NCT03424733Phase 4Unknown

Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects

Started Sep 2017
50 enrolled
Multiple Sclerosis
NCT02491684Phase 2Completed

A Study in Asthma Patients to Evaluate Efficacy, Safety and Tolerability of 14 Days Once Daily Inhaled Interferon Beta-1a After the Onset of Symptoms of an Upper Respiratory Tract Infection

Started Jul 2015
121 enrolled
Asthma